MOLECULAR PARTNERS AG (MOLN)
About MOLECULAR PARTNERS AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $153.8M
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $153.8M
- Shares outstanding
- 39.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 16, 2021
Molecular Partners AG (MOLN) Stock Price
- Trading 24% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review MOLECULAR PARTNERS AG.
Write a review
News about MOLECULAR PARTNERS AG
News & sentiment via Polygon.io
Molecular Partners AG: frequently asked questions
Is Molecular Partners AG an American company?
Molecular Partners AG is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Molecular Partners AG publicly traded?
Yes — Molecular Partners AG is a publicly traded company. Its stock trades under the ticker symbol MOLN on the NASDAQ.
What does Molecular Partners AG do?
Molecular Partners AG is an American Pharmaceuticals company in the Health & Beauty sector.
